Zosano Pharma

Zosano Pharma focuses on creating better products with its innovative drug delivery technology. Zosano's objective is to discover and develop therapeutic drug candidates that address large unmet medical needs or have a significant potential for commercialization. It was founded in 2006 and headquartered in Fremont, California.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zosano Pharma Corp (NASDAQ: ZSAN) shares are trading lower by 44.35% at $0.98 after the company announced it filed a voluntary petition for relief under chapter 11. Zosano says the company continues to operate its business as a "debtor-in-possession" under the jurisdiction of the.

Why Zosano Pharma Shares Are Getting Hammered Today

FREMONT, Calif., May 13, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2022. All share and per share information included in these financial results and statements has been retroactively adjusted to give effect to our April 11, 2022 1-for-35 reverse stock split.

Zosano Pharma Reports First Quarter 2022 Financial Results

The FDA had granted Zosano Pharma Corporation (NASDAQ: ZSAN) a twelve-month extension to April 20, 2023, to resubmit its M207 marketing application. However, to preserve its capital and cash resources, Zosano has suspended its M207 program.

Zosano Pharma Announces Additional Workforce Layoff

FREMONT, Calif., April 29, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today provided a corporate update.

Zosano Pharma Provides Corporate Update

ZSAN stock appears to be soaring because the company carried out a reverse stock split in order to stay compliant with the Nasdaq's rules. The post Is Zosano Pharma (ZSAN) Stock Really Up 3,000% Today?

Is Zosano Pharma (ZSAN) Stock Really Up 3,000% Today?

Zosano Pharma Corporation (NASDAQ: ZSAN) recently announced that its Board of Directors has approved a 1-for-35 reverse stock split of the company's common stock. And the reverse split has gone into effect.

Zosano Pharma (ZSAN) Stock: 1-For-35 Reverse Split Goes Into Effect

ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022 ZSAN common stock expected to begin trading on a split-adjusted basis on April 12, 2022

Zosano Pharma Announces Reverse Stock Split Effective Today

Energy Services of America Corp

China Rapid Finance

Are these the best penny stocks to watch under $5 right now? The post Best Stocks to Buy Under $5?

Best Stocks to Buy Under $5? Check These 3 Out

FREMONT, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the fourth quarter and year ended December 31, 2021, as well as business updates.

Zosano Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results

The FDA has issued a response letter to Zosano Pharma Corp (NASDAQ: ZSAN) regarding its resubmission of the 505(b)(2) New Drug Application for M207 (zolmitriptan microneedle system).  The response letter stated that the FDA did not consider the resubmitted M207 application.

FDA Rejects Zosano Pharma's Application For Zolmitriptan Microneedle System Again, Shares Plunge

The stock price of Zosano Pharma Corp (NASDAQ: ZSAN) fell by over 49% pre-market today. This is why it happened.

Zosano Pharma (ZSAN) Stock: Why The Price Substantially Fell Today

FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30 per unit. The warrants have an exercise price of $0.30 per share, are immediately exercisable and will expire five years from the date of issuance. Zosano has granted the underwriter a 30-day option to purchase up to an additional 7,687,500 shares of common stock and/or additional warrants to purchase up to 7,687,500 shares of common stock.

Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants

FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it is commencing an underwritten public offering of units consisting of shares of common stock and warrants to purchase common stock. All of the units in the offering are to be sold by Zosano. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Zosano Pharma Announces Proposed Public Offering of Common Stock and Warrants

—Data published in the Journal of Vaccines and Immunology— —Data published in the Journal of Vaccines and Immunology—

CORRECTION - Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

Zosano Pharma Corporation (NASDAQ: ZSAN) announced the publication of Phase 1 trial data of influenza vaccine in the Journal of Vaccines and Immunology.  The data demonstrated that a low dose of a trivalent influenza vaccine administered via its transdermal microneedle system produced antibody levels and was generally well tolerated.

Zosano Pharma Announces Publication Of Early Data On Influenza Vaccine

Zosano Pharma Announces Publication of Clinical Data Demonstrating Comparable Immunogenicity of a Trivalent Influenza Vaccine Formulated on its Transdermal Microneedle System Versus an Intramuscular Injection of the Vaccine at a Higher Dose

FREMONT, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced changes to its board of directors, including the appointment of Elaine M. Yang.

Zosano Pharma Announces Changes to Board of Directors; Appoints Cross Functional Business Executive Elaine M. Yang

Avinger

Camber Energy

Today's hot penny stocks are catching the eyes of investors and we're diving into everything investors need to know about them on Wednesday! The post Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?

Today's Hot Penny Stocks: What's Moving ZSAN, AVGR and CEI Higher Wednesday?

Zosano Pharma Corporation (ZSAN) delivered earnings and revenue surprises of 0.00% and -10.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Zosano Pharma Corporation (ZSAN) Reports Q3 Loss, Misses Revenue Estimates

FREMONT, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter ended September 30, 2021, as well as business highlights.

Zosano Pharma Reports Third Quarter 2021 Financial Results

The stock price of Zosano Pharma Corp (NASDAQ: ZSAN) increased by over 40% pre-market today. This is why it happened.

ZSAN Stock: Why The Price Surged Today

FREMONT, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the company has been granted a Type C written response only meeting with the U.S. Food and Drug Administration (“FDA”) regarding the resubmission of the M207 (zolmitriptan transdermal microneedle system) 505(b)(2) New Drug Application (“NDA”) following receipt of preliminary top-line results from the pharmacokinetic (“PK”) study.

Zosano Pharma Granted Type C Meeting with FDA Regarding NDA Resubmission for M207 Following Preliminary Top-Line Pharmacokinetic Study Results

FREMONT, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the H.C. Wainwright Global Investment Conference available on demand beginning September 13, 2021 at 7:00am ET.

Zosano Pharma to Present at the H.C. Wainwright Virtual Global Investment Conference

Zosano Pharma Corporation (ZSAN) delivered earnings and revenue surprises of 0.00% and -30.37%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Zosano Pharma Corporation (ZSAN) Reports Q2 Loss, Misses Revenue Estimates

FREMONT, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2021, as well as business highlights.

News for Zosano Pharma Stock (ZSAN)